Infliximab versus Adalimumab: Can We Choose the Right One for the Right Patients with Ulcerative Colitis?

참고문헌 (23)

1. Lee Yong Il, "Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis", Gut and Liver, 15(2), pp.232~242 (2021), 거트앤리버 소화기연관학회협의회[DOI]
2. Singh S, "Comparison of infliximab and adalimumab in biologic-naive patients with ulcerative colitis : a nationwide Danish cohort study", Clin Gastroenterol Hepatol, 15, pp.1218~1225 (2017)
3. Singh S, "Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis", Aliment Pharmacol Ther, 43, pp.994~1003 (2016)
4. Danese S, "Biological agents for moderately to severely active ulcerative colitis : a systematic review and network meta-analysis", Ann Intern Med, 160, pp.704~711 (2014)
5. Stidham RW, "Systematic review with network meta-analysis : the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis", Aliment Pharmacol Ther, 39, pp.660~671 (2014)
6. Thorlund K, "Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis : a network metaanalysis accounting for differences in trial designs", Expert Rev Gastroenterol Hepatol, 9, pp.693~700 (2015)
7. Oh EH, "Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease", World J Gastroenterol, 23, pp.1489~1496 (2017)
8. Vande Casteele N, "American Gastroenterological Association Institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases", Gastroenterology, 153, pp.835~857 (2017)
9. Park SH, "Severe disease activity and cytomegalovirus colitis are predictive of a nonresponse to infliximab in patients with ulcerative colitis", Dig Dis Sci, 58, pp.3592~3599 (2013)
10. Hsu-Heng Yen, "Epidemiological trend in inflammatory bowel disease in Taiwan from 2001 to 2015: a nationwide population-based study", Intestinal research, 17(1), pp.54~62 (2019), 대한장연구학회[DOI]
11. Park SH, "A 30-year trend analysis in the epidemiology of inflammatory bowel disease in the Songpa-Kangdong district of Seoul, Korea in 1986-2015", J Crohns Colitis, 13, pp.1410~1417 (2019)
12. Ng SC, "Epidemiology of inflammatory bowel disease from 1981 to 2014 : results from a territory-wide population-based registry in Hong Kong", Inflamm Bowel Dis, 22, pp.1954~1960 (2016)
13. Okabayashi S, "Inflammatory bowel disease in Japan : is it similar to or different from westerns?", J Anus Rectum Colon, 4, pp.1~13 (2020)
14. Zeng Z, "Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China : a prospective populationbased study", J Gastroenterol Hepatol, 28, pp.1148~1153 (2013)
15. Cha JM, "Long-term prognosis of ulcerative colitis and its temporal changes between 1986 and 2015 in a population-based cohort in the Songpa-Kangdong district of Seoul, Korea", Gut, 69, pp.1432~1440 (2020)
16. Satimai Aniwan, "Temporal trend in the natural history of ulcerative colitis in a country with a low incidence of ulcerative colitis from 2000 through 2018", Intestinal research, 19(2), pp.186~193 (2021), 대한장연구학회[DOI]
17. Park SH, "Long-term outcomes of infliximab treatment in 582 Korean patients with Crohn’s disease : a hospital-based cohort study", Dig Dis Sci, 61, pp.2060~2067 (2016)
18. Eun Hye Oh, "Long-term Outcomes of Adalimumab Therapy in Korean Patients with Ulcerative Colitis: A Hospital-Based Cohort Study", Gut and Liver, 14(3), pp.347~356 (2020), 거트앤리버 소화기연관학회협의회[DOI]
19. Tadakazu Hisamatsu, "Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease: 3-year results from a real-world study", Intestinal research, 19(4), pp.408~418 (2021), 대한장연구학회[DOI]
20. Haruhiko Ogata, "Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study", Intestinal research, 19(4), pp.419~429 (2021), 대한장연구학회[DOI]
21. Seo H, "Long-term outcomes of infliximab treatment and predictors of response in 195 patients with ulcerative colitis : a hospital-based cohort study from Korea", Scand J Gastroenterol, 52, pp.857~863 (2017)
22. Seo H, "Long-term outcomes of adalimumab treatment in 254 patients with Crohn’s disease : a hospital-based cohort study from Korea", Dig Dis Sci, 62, pp.2882~2893 (2017)
23. Chang Kyun Lee, "A new opportunity for innovative inflammatory bowel disease research: the moderate-to-severe ulcerative colitis in Korea (MOSAIK) cohort study", Intestinal research, 17(1), pp.1~5 (2019), 대한장연구학회[DOI]

관련 논문AI추천